News | April 07, 2008

Stubborn High Blood Pressure May Need Special Care

April 8, 2008 - People who are taking three or more drugs and still have high blood pressure have a condition known as resistant hypertension that may require special treatment, the American Heart Association said on Monday.

The guidelines are intended to help doctors and patients identify and control resistant hypertension, which affects as many as 30 percent of people with high blood pressure.

"It may be the fastest-growing component of hypertension in general - those patients needing three or more medicines," David Calhoun, M.D., of the University of Alabama at Birmingham and chair of the association's guideline writing committee said in a telephone interview.

Given that older age and obesity are two of the strongest risk factors associated with this kind of hypertension, the condition will likely become increasingly common as the U.S. population ages and grows heavier, Dr. Calhoun said.

Under the new guidelines, published online in the journal Hypertension, resistant hypertension also includes people who must take four or more drugs before they can get their blood pressure under control.

High blood pressure affects about 73 million people in the United States and an estimated 1 billion people globally. Poorly controlled hypertension increases the risk of heart attacks, stroke, kidney failure and heart failure.

"These patients with resistant hypertension are probably at even increased risk because of their long-standing, poorly controlled hypertension," Dr. Calhoun said.

Dr. Calhoun said the guidelines are the first to specifically address the treatment of resistant hypertension, which he said may be brought on by underlying conditions that need to be managed.
"Obesity, a high-salt diet, and sleep apnea are common contributing causes," he said. Resistant hypertension may also result from an excess of a hormone produced in the adrenal gland known as aldosterone, which can promote fluid retention.

Kidney disease and diabetes are also important contributors, Dr. Calhoun said.

The new guidelines stress that treatment should be tailored to individual patients and their underlying conditions.

If blood pressure cannot be controlled after working with a general doctor for six months, Dr. Calhoun said people should referred to a specialist.

(Editing by Maggie Fox and Eric Walsh)


For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init